ArticleThe Journal of dermatology2026
Toxic Epidermal Necrolysis and Mortality: A Danish Cohort Study With 30 Years of Follow-Up.
Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Data on Severe Cutaneous Adverse Reactions to Drugs.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Toxic epidermal necrolysis (TEN) is a rare, life-threatening dermatologic condition, typically triggered by medications. While increased short-term mortality in this group is well documented, few studies have quantified this risk over extended follow-up. We aimed to examine both short- and long-term mortality and assess whether excess mortality persists beyond the acute phase. We conducted a nationwide, register-based matched cohort study using Danish health registries. Patients with a first-time hospital diagnosis of TEN between 1995 and 2024 were included and matched 1:100 on age and sex with population controls. Short-term mortality (30- and 90-day) was calculated, and long-term mortality was assessed overall and in a landmark analysis restricted to 2-year survivors with newly matched controls. We identified 145 individuals hospitalized with TEN and matched them to 14 500 population controls. The mean age was 56 years, and half were female. Short-term mortality was high, with 28% dying within 90 days. Median survival was 4.77 years (95% CI: 2.02-9.46) for TEN patients versus 25.96 years (95% CI: 25.19-27.20) for controls. Two years after diagnosis, TEN patients still had almost triple the mortality risk compared to controls (HR 3.30; 95% CI: 2.34-4.66). Excess mortality was also observed among patients without any recorded comorbidities at the time of diagnosis, indicating that the increased risk was not solely attributable to preexisting health conditions. Most deaths were due to natural causes; fewer than five were attributed to unnatural or unknown causes. In conclusion, this study quantifies the long-term reduction in survival following TEN. Our estimates captured the real-world excess mortality burden of TEN, arising from the acute disease, sequelae, or comorbidities, thus providing a clinically relevant picture of long-term prognosis. The increased mortality risk was not explained by baseline comorbidity alone, underscoring that TEN itself contributes to a poorer long-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.